Can NewAmsterdam Pharma Company cover its short-term obligations?

Its current ratio is 9.76 — current assets exceed current liabilities.

Where does NewAmsterdam Pharma Company's balance sheet data come from?

Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

NewAmsterdam Pharma Company NAMS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$457.61M-38.9%	$490M-36.5%	$538.41M+27.4%	$563.86M—	$748.42M—
Short-term investments	$178.5M—	$146.24M—	$164.54M—	——	——
Restricted cash	——	——	——	——	——
Prepaid expenses and other current assets	$20.6M+133%	$38.14M+57.1%	$28.07M+85.4%	$30.69M—	$8.83M—
Total current assets	$658.04M-19.5%	$675.7M-21.7%	$732.33M+67.2%	$769.85M—	$817.3M—
Property and equipment, net	$379K+59.2%	$383K+58.3%	$323K+39.8%	$312K—	$238K—
Operating lease right-of-use assets	$21K-94.3%	$185K-57.1%	$246K-50.1%	$308K—	$369K—
Goodwill	$375K-25.3%	$407K-23.8%	$439K-26.0%	$470K—	$502K—
Total assets	$732.64M-10.5%	$769.28M-11.0%	$786.43M+79.1%	$815.11M—	$818.41M—
Accounts payable	$26.59M+14.9%	$24.58M-3.9%	$20.36M-46.1%	$23.77M+10.5%	$23.15M+12.6%
Deferred revenue	——	——	——	——	——
Operating lease liabilities, current	$23K-90.9%	$136K-44.7%	$181K-24.6%	$225K—	$252K—
Total current liabilities	$67.42M+64.8%	$85.79M-19.8%	$58.27M+41.2%	$36.51M—	$40.91M—
Operating lease liabilities, non-current	——	$66K—	$85K—	$103K—	$137K—
Total liabilities	$67.42M+64.2%	$85.85M-19.9%	$58.36M-3.3%	$36.62M—	$41.05M—
Common stock	$14.59M+4.5%	$14.28M+6.2%	$14.11M+23.4%	$14.01M—	$13.97M—
Additional paid-in capital	$1.46B+7.4%	$1.43B+9.9%	$1.4B+68.4%	$1.38B—	$1.36B—
Retained earnings	-$810.83M-35.6%	-$762.39M-36.5%	-$687.47M-47.4%	-$615.46M—	-$598.1M—
Accumulated other comprehensive income (loss)	$4.22M-4.8%	$4.79M+7.3%	$4.64M+4.9%	$4.33M—	$4.43M—
Total stockholders' equity	$665.22M-14.4%	$683.43M-9.8%	$728.07M+92.2%	$778.5M+101%	$777.36M+88.8%
Total liabilities and stockholders' equity	$732.64M-10.5%	$769.28M-11.0%	$786.43M+79.1%	$815.11M—	$818.41M—
Short- term Investments	$178.5M—	$146.24M—	$164.54M—	——	——
Goodwill and Intangible Assets, Net	$375K-25.3%	$407K-23.8%	$439K-26.0%	$470K—	$502K—
Net Investment in Lease	$21K-94.3%	$185K-57.1%	$246K-50.1%	$308K—	$369K—
Goodwill and intangible assets, net	$375K-25.3%	$407K-23.8%	$439K-26.0%	$470K—	$502K—
Operating lease right-of-use assets	$21K-94.3%	$185K-57.1%	$246K-50.1%	$308K—	$369K—
Operating Lease Right-of-Use Assets in Other Assets	$21K-94.3%	$185K-57.1%	$246K-50.1%	$308K—	$369K—
Accrued liabilities and other current	$5.09M-36.5%	$15.42M+13.3%	$10.1M-4.6%	$9.46M—	$8.02M—
Deferred income	——	——	——	——	$3.03M—
Derivative Liability, Current	$50.23M+114%	$57.27M+52.7%	$44.36M+135%	$20.93M—	$23.52M—
Derivative Liabilities - Fair Value	$50.23M+114%	$57.27M+52.7%	$44.36M+135%	$20.93M—	$23.52M—
Total debt	$23K-94.1%	$202K-54.9%	$266K-47.4%	$328K—	$389K—
Additional paid-in capital	$1.46B+7.4%	$1.43B+9.9%	$1.4B+68.4%	$1.38B—	$1.36B—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$14.59M+4.5%	$14.28M+6.2%	$14.11M+23.4%	$14.01M—	$13.97M—
Prepaid ship and debits	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can NewAmsterdam Pharma Company cover its short-term obligations?: Its current ratio is 9.76 — current assets exceed current liabilities.
Where does NewAmsterdam Pharma Company's balance sheet data come from?: Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.